Navigation Links
Organovo Announces $6.5 Million Private Placement to Advance 3D Bioprinting for Medical Applications
Date:2/14/2012

SAN DIEGO, Feb. 14, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQB: ONVO) ("Organovo") today announced the successful completion of a merger on February 8, 2012, with Organovo, Inc. (the "Merger"), a company focused on the development of three-dimensional bioprinting technology for research and medical applications.  Concurrent with the Merger, Organovo closed a private placement consisting of approximately 6.5 million units of its securities to qualified accredited investors, for total gross proceeds of $6.5 million.

"Organovo's advanced bioprinting platform can replicate essential biology for research, drug discovery and development and, eventually, for therapeutic applications," stated Keith Murphy, chief executive officer of Organovo. "We have found success in achieving early revenue through strategic collaborations, and this funding will allow us to extend the reach and uses of 3D bioprinting through growth and innovation in the coming years."

Organovo will continue the business of Organovo, Inc., headquartered in San Diego, as a wholly-owned subsidiary under the leadership of Organovo, Inc.'s current management team, headed by Chief Executive Officer Keith Murphy. In completing the Merger, Organovo issued approximately 22.4 million shares of its common stock to the holders of Organovo, Inc. common stock. The merged company will be quoted on the OTC markets and on the OTCQB under the symbol "ONVO" beginning Tuesday, February 14, 2012. 

The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be resold absent registration under or exemption from such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933.

About Organovo Holdings, Inc.

Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. The company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types. Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine. Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development. Organovo's bioprinting technology can also be developed to create surgical tissues direct therapy. Organovo leads the way in solving complex medical research problems and building the future of medicine. For more information, please visit http://www.organovo.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.


'/>"/>
SOURCE Organovo Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ZONARE Medical Systems Announces Appointment of Timothy A. Marcotte as President and Chief Executive Officer
2. Dynatronics Announces Second Quarter Results
3. Perrigo Announces the Launch of Loratadine-D 12 Store Brand Labels -- the First Store Brand Launch That Compares to Claritin-D® 12
4. CareFusion Announces $500 Million Share Repurchase Program
5. Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
6. Faruqi & Faruqi, LLP Announces Investigation of BioSante Pharmaceuticals, Inc.
7. Unilife Corporation Announces Financial Results for Fiscal Year 2012 Second Quarter
8. Halozyme Announces Proposed Public Offering of Common Stock
9. Anthera Announces Fourth Quarter 2011 Financial Report and Conference Call
10. Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models
11. Resource Anesthesia Adds Locations Under Management, Announces Addition of HealthStream LearningCenter®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 2016 Research and ... Acute lymphocytic Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic ...
(Date:5/3/2016)... TUCSON, Ariz. , May 3, 2016  As ... twice contracted rheumatic fever, which damaged his heart. ... But by June 2013, Shepherd,s heart was ... days from death. On June 20, 2013, the ... temporary Total Artificial Heart (TAH-t). Like a heart transplant, ...
(Date:5/3/2016)... , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is ... a video of two patients who tell their personal story and encourage those at risk ... Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
Breaking Medicine Technology:
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... ... recently partnered with local company MitoXcell in preparation of the launch of her new ... jump start plan is a nutritional guide designed to jump start a new healthy ...
(Date:5/4/2016)... Hills, CA (PRWEB) , ... May 04, 2016 , ... ... care that ex-supermodel Janice Dickinson needed following breast cancer surgery. In March 2016, the ... situ, a type of breast cancer that occurs in the milk ducts, according to ...
(Date:5/4/2016)... Ventura, CA (PRWEB) , ... May 04, 2016 , ... ... cutting-edge technology to help restore its patients’ health, is hosting a free seminar on ... and will be held at Advanced Spine & Sport, 4601 Telephone Road, Suite 110, ...
(Date:5/4/2016)... Wisconsin (PRWEB) , ... May ... ... delivers next-level compression and support for knees, ankles, and elbows. Engineered with ... , Innovative 3D flat-bed manufacturing (opposed to ineffective circular knitting, common in ...
(Date:5/4/2016)... ... May 03, 2016 – (PRWEB) May ... and child products, today revealed the non-toxic benefits of its Tutti ... deal with teething pain is just part of the story. These ... are BPA-, PVC-, and phthalate-free. , “Many baby toys contain ...
Breaking Medicine News(10 mins):